Responses
Inflammatory bowel disease
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Compose a Response to This Article
Other responses
No responses have been published for this article.